GM-CSF is a major regulator of myelopoiesis. Recombinant human GM-CSF (250 micrograms/m2 per day i.v.) was used prior to chemotherapy ("3 + 7" scheme) to recruit leukemic blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of
Granulocyte-Macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia
β Scribed by Paul S. Frenette; Jane F. Desforges; David P. Schenkein; Arthur Rabson; Christopher A. Siapack; Dr. Kenneth B. Miller
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 783 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Based on the presence of immature cells in fetal blood, and in an attempt to shorten the cytogenetic reporting time, three simultaneous one-day culture regimes were established in 23 fetal blood samples: (a) the standard phytohemagglutinin (PHA)-stimulated lymphocytes culture, (b) a culture using th
## Abstract As sensitization of leukemic cells with granulocyte colonyβstimulating factor (Gβcsf) can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML), a pilot study was conducted in order to evaluate the effect of Gβcsf priming combined with lowβdose chemotherapy in patient